methylnaphthidate (also known as hdmp-28) is a novel synthetic stimulant substance of the substituted naphthidate and piperidine chemical classes. it is a structural analog of the commonly prescribed adhd drug methylphenidate (e.g. ritalin, concerta) that produces moderately stimulating effects when administered.
like members of the phenidate class, methylnaphthidate is believed to act as a monoamine reuptake inhibitor. however, it has been reported to display distinct differences in its subjective effects by not behaving as a traditional dopaminergic stimulant. this has been speculated to owe itself to its appreciable effects on serotonin reuptake inhibition that is not observed in typical methylphenidate analogs.
very little data exists about the pharmacological properties, metabolism, and toxicity of methylnaphthidate, and it has little history of human usage. it is sometimes commercially distributed as a grey-area research chemical by online vendors alongside other methylphenidate analogs like ethylphenidate, isopropylphenidate, and 4f-mph. it is highly advised to approach this and poorly understood stimulant substance with the proper amount of precaution and harm reduction practices if choosing to use it.
the main structural differences between methylnaphthidate and methylphenidate in chemical substance is the replacement of the core phenyl ring with with a napthalene group.
methylnaphthidate is thought to act primarily as a monoamine triple reuptake inhibitor, meaning it effectively elevates the levels of dopamine, noradrenaline and serotonin neurotransmitters throughout the brain and cns by binding to and partially blocking the transporter proteins that normally clear out these monoamines from the synaptic cleft. this allows these molecules to accumulate throughout the brain, particularly within the reward pathways in the brain, resulting in stimulating and euphoric effects.